Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy
This study suggests that the MSP drug delivery platform holds significant potential for clinical use in improving RA therapy by enabling the sustained slow release of MTX, thereby enhancing therapeutic outcomes and minimizing side effects associated with conventional burst-release drug administration.
Authors
- Alberto Migliore (ORCID: https://orcid.org/0000-0002-3397-6478)
- Roberta Bernardini (ORCID: https://orcid.org/0000-0002-1675-0645)
- Valeria Palumbo (ORCID: https://orcid.org/0000-0001-7756-6676)
- Christi Abbate (ORCID: https://orcid.org/0009-0000-8953-7266)
- Francesca Cavalieri (ORCID: https://orcid.org/0000-0001-5391-5069)
- Mariano Venanzi (ORCID: https://orcid.org/0000-0001-9364-7441)
- Antonio Rinaldi (ORCID: https://orcid.org/0000-0002-3087-2649)
- Manuel Scimeca (ORCID: https://orcid.org/0000-0003-0585-1309)
- Maurizio Mattei (ORCID: https://orcid.org/0000-0002-0814-8873)
- Patrizia Nadia Hanieh (ORCID: https://orcid.org/0000-0003-3278-8376)
- Rita Cimino (ORCID: https://orcid.org/0000-0003-3230-1863)
- Noemi Fiaschini (ORCID: https://orcid.org/0000-0003-1094-7743)
- Daniela Ariaudo
- Elena Romano (ORCID: https://orcid.org/0000-0002-8501-2590)
Institutions
- University of Rome Tor Vergata (IT)
- Fatebenefratelli Hospital (IT)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3390/pharmaceutics16121593
- Citations
- 4
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- European Commission
- Regione Lazio